94 results on '"Bruin, Gerard"'
Search Results
2. In reply: Use of a second ventilatory circuit when using a double-lumen endotracheal tube
3. AXT914 a novel, orally-active parathyroid hormone-releasing drug in two early studies of healthy volunteers and postmenopausal women
4. ATF936, a novel oral calcilytic, increases bone mineral density in rats and transiently releases parathyroid hormone in humans
5. β-Defensin 2 is a responsive biomarker of IL-17A–driven skin pathology in patients with psoriasis
6. Secukinumab rapidly reduces markers of both keratinocyte proliferation and skin integrity in psoriasis: 1264
7. Secukinumab, a novel anti–IL-17A antibody, exhibits low immunogenicity in clinical trials and human in vitro assays: 1320
8. High Efficacy, Safety, and Tolerability of Secukinumab Injection with 2 mL Auto-injector (300 Mg) in Adult Patients with Moderate to Severe Plaque Psoriasis: 52-week Results from MATURE, a Randomised, Placebo-controlled Trial
9. Efficacy, pharmacokinetics, and tolerability of subcutaneous secukinumab injections with 2 mL prefilled syringes (300 mg) in adult subjects with moderate to severe plaque psoriasis
10. Secukinumab administration by a 2 mL autoinjector demonstrates high efficacy with comparable safety and tolerability in adult patients with plaque psoriasis: 16-week results from MATURE
11. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial*.
12. Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study
13. Thoracoabdominal Aortic Aneurysm Repair: A Prospective Cohort Study of 121 Cases
14. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohnʼs disease: unexpected results of a randomised, double-blind placebo-controlled trial
15. Secukinumab demonstrates efficacy, safety, and tolerability upon administration by 2 ml autoinjector in adult patients with plaque psoriasis: 52‐week results from MATURE, a randomized, placebo‐controlled trial.
16. A microplate solid scintillation counter as a radioactivity detector for high performance liquid chromatography in drug metabolism: Validation and applications
17. Abstracts of lectures and posters pharmaceutical and biomedical analysis meeting
18. A cohort study of coagulation parameters and the use of blood products in surgery of the thoracic and thoracoabdominal aorta
19. Kommerell’s diverticulum and aneurysmal right-sided aortic arch: A case report and review of the literature
20. Lung re-inflation after one-lung ventilation for thoracic surgery: importance of clamping the dependent lung
21. 27599 Secukinumab administration by a 2 mL autoinjector demonstrates high efficacy with comparable safety and tolerability in adult patients with plaque psoriasis: 16-week results from MATURE
22. 27519 Efficacy, pharmacokinetics, and tolerability of subcutaneous secukinumab injections with 2 mL prefilled syringes (300 mg) in adult subjects with moderate to severe plaque psoriasis
23. 25482 Secukinumab efficacy and safety profile in pediatric patients with severe chronic plaque psoriasis up to 1 year
24. Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis.
25. Comparison of pharmacokinetics, safety and tolerability of secukinumab administered subcutaneously using different delivery systems in healthy volunteers and in psoriasis patients.
26. Secukinumab Treatment Does Not Alter the Pharmacokinetics of the Cytochrome P450 3A4 Substrate Midazolam in Patients With Moderate to Severe Psoriasis.
27. Reply
28. Intubating conditions and correct application of cricoid pressure during rapid sequence induction: who should hold the mask?
29. Population Pharmacokinetic Modeling of Secukinumab in Patients With Moderate to Severe Psoriasis.
30. On-Line Preconcentration and Separation of Antisense Oligonucleotides by ITP-CE in Dextran-Filled Capillaries.
31. Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis.
32. Secukinumab distributes into dermal interstitial fluid of psoriasis patients as demonstrated by open flow microperfusion.
33. Immunoaffinity screening with capillary electrochromatography.
34. Recent developments in electrokinetically driven analysis on microfabricated devices.
35. Fritless capillary electrochromatography.
36. Hologram-based refractive index detector for capillary electrophoresis: Separation of metal ions.
37. Preconcentration and separation of antisense oligonucleotides by on-column isotachophoresis and capillary electrophoresis in polymer-filled capillaries.
38. Integrated chip-based capillary electrophoresis.
39. Purple blotch disease of garlic: Development of the disease in Chiangmai‐Lamphun valley, Northern Thailand, considered in relation to fungicide use and other farming practices.
40. 263 Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in patients with psoriatic arthritis and ankylosing spondylitis during a 52week treatment period.
41. Reply.
42. Theoretical and experimental aspects of indirect detection in capillary electrophoresis
43. Stability measurements of antisense oligonucleotides by capillary gel electrophoresis
44. Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety.
45. Secukinumab, a novel anti-IL-17A antibody, exhibits low immunogenicity in clinical trials and human in vitro assays.
46. Absorption, Distribution, Metabolism, and Excretion of Therapeutic Proteins: Current Industry Practices and Future Perspectives.
47. Characterizing the Pharmacokinetics and Biodistribution of Therapeutic Proteins: An Industry White Paper.
48. Reply: To PMID 25141833.
49. Nanoparticle flotation collectors--the influence of particle softness.
50. The anti-IL-17A antibody secukinumab does not attenuate ozone-induced airway neutrophilia in healthy volunteers.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.